Skip to main content Accessibility help
×
Hostname: page-component-7b7567c8c-fvjsw Total loading time: 0 Render date: 2026-11-16T08:14:41.649Z Has data issue: false hasContentIssue false

9 - Spasticity and botulinum toxin

Published online by Cambridge University Press:  22 August 2009

Michael P. Barnes
Affiliation:
Professor of Neurological Rehabilitation Walkergate Park International Centre for Neurorehabilitation and Neuropsychiatry, Newcastle upon Tyne, UK
Elizabeth C. Davis
Affiliation:
Consultant in Rehabilitation Medicine Walkergate Park International Centre for Neurorehabilitation and Neuropsychiatry, Newcastle upon Tyne, UK
Michael P. Barnes
Affiliation:
University of Newcastle upon Tyne
Garth R. Johnson
Affiliation:
University of Newcastle upon Tyne
Get access

Summary

Introduction

Botulinum toxin (BoNT) is the most potent neurotoxin known, and its clinical effects have been recognized since the end of the nineteenth century. The toxin is produced by the gram-negative anaerobic bacterium Clostridium botulinum and ingestion can produce botulism, a rare and often fatal paralytic illness.

The paralytic effect of the toxin is due to blockade of neuromuscular transmission (Burgen et al., 1949). Injection of BoNT into a muscle causes irreversible chemodenervation and local paralysis. It was this discovery that led to the development of the toxin as a therapeutic tool. It is now used clinically for a wide range of conditions (Jankovic, 1994).

There has been burgeoning interest in the medical use of BoNT, particularly since its efficacy and safety have been demonstrated. Its use in the management of spasticity is now well established. This chapter reviews its mode of action and current therapeutic use in spasticity.

Clinical pharmacology

There are seven immunologically distinct serotypes of botulinum toxin (labelled A to G); there are two types in routine clinical use – BoNT type A (BoNT-A) and BoNT type B (BoNT-B). Most of the studies with regard to botulinum and spasticity have been conducted using type A toxin, but type B toxin is in commercial use and is also used in the management of spasticity.

Information

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Spasticity and botulinum toxin
    • By Michael P. Barnes, Professor of Neurological Rehabilitation Walkergate Park International Centre for Neurorehabilitation and Neuropsychiatry, Newcastle upon Tyne, UK, Elizabeth C. Davis, Consultant in Rehabilitation Medicine Walkergate Park International Centre for Neurorehabilitation and Neuropsychiatry, Newcastle upon Tyne, UK
  • Edited by Michael P. Barnes, University of Newcastle upon Tyne, Garth R. Johnson, University of Newcastle upon Tyne
  • Book: Upper Motor Neurone Syndrome and Spasticity
  • Online publication: 22 August 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511544866.010
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Spasticity and botulinum toxin
    • By Michael P. Barnes, Professor of Neurological Rehabilitation Walkergate Park International Centre for Neurorehabilitation and Neuropsychiatry, Newcastle upon Tyne, UK, Elizabeth C. Davis, Consultant in Rehabilitation Medicine Walkergate Park International Centre for Neurorehabilitation and Neuropsychiatry, Newcastle upon Tyne, UK
  • Edited by Michael P. Barnes, University of Newcastle upon Tyne, Garth R. Johnson, University of Newcastle upon Tyne
  • Book: Upper Motor Neurone Syndrome and Spasticity
  • Online publication: 22 August 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511544866.010
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Spasticity and botulinum toxin
    • By Michael P. Barnes, Professor of Neurological Rehabilitation Walkergate Park International Centre for Neurorehabilitation and Neuropsychiatry, Newcastle upon Tyne, UK, Elizabeth C. Davis, Consultant in Rehabilitation Medicine Walkergate Park International Centre for Neurorehabilitation and Neuropsychiatry, Newcastle upon Tyne, UK
  • Edited by Michael P. Barnes, University of Newcastle upon Tyne, Garth R. Johnson, University of Newcastle upon Tyne
  • Book: Upper Motor Neurone Syndrome and Spasticity
  • Online publication: 22 August 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511544866.010
Available formats
×